Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Prospective, Open-Label Registry Study of the Utilization of EsoGuard, on Samples Collected Using EsoCheck, in an At-Risk Population Undergoing Standard of Care Screening for, and Management of, Previously Undiagnosed Barrett's Esophagus and/or Esophageal Adenocarcinoma

NCT05965999 is registered in ClinicalTrials.gov with Lucid Diagnostics, Inc. as lead sponsor.

NCT NCT05965999
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05965999 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Prospective, Open-Label Registry Study of the Utilization of EsoGuard, on Samples Collected Using EsoCheck, in an At-Risk Population Undergoing Standard of Care Screening for, and Management of, Previously Undiagnosed Barrett's Esophagus and/or Esophageal Adenocarcinoma
Lead sponsor
Lucid Diagnostics, Inc.
Phase
Observational
Overall status
Recruiting
Start date
April 11, 2023
Completion date
December 31, 2027
Enrollment
8,000 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

barrett esophagus, barrett's esophagus without dysplasia, barretts esophagus with dysplasia, esophageal adenocarcinoma